Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRGNASDAQ:EDSANASDAQ:LPCNOTCMKTS:SPRCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRGBullfrog AI$1.81+2.3%$1.81$1.23▼$4.84$17.04M0.77389,043 shs106,600 shsEDSAEdesa Biotech$2.37-1.3%$2.34$1.55▼$5.59$16.65M0.6489,733 shs4,307 shsLPCNLipocine$3.26-0.6%$3.21$2.75▼$11.79$17.44M1.5132,179 shs7,419 shsSPRCYSciSparc$4.00-19.0%$4.00$2.75▼$12.25$4.15M-0.0810,035 shs12,500 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRGBullfrog AI-4.32%+6.63%+4.12%-21.68%-39.18%EDSAEdesa Biotech+1.69%+0.84%-4.00%+20.60%-45.70%LPCNLipocine+2.82%+8.97%0.00%-28.23%-31.63%SPRCYSciSparc0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRGBullfrog AI0.3501 of 5 stars0.02.00.00.01.12.50.0EDSAEdesa Biotech3.1197 of 5 stars3.55.00.00.02.61.70.6LPCNLipocine2.5699 of 5 stars3.55.00.00.02.20.00.6SPRCYSciSparcN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRGBullfrog AI 0.00N/AN/AN/AEDSAEdesa Biotech 3.00Buy$21.00786.08% UpsideLPCNLipocine 3.00Buy$10.00206.75% UpsideSPRCYSciSparc 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SPRCY, LPCN, BFRG, and EDSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRGBullfrog AI$60K284.02N/AN/A$0.43 per share4.21EDSAEdesa BiotechN/AN/AN/AN/A$0.18 per shareN/ALPCNLipocine$11.20M1.56N/AN/A$3.83 per share0.85SPRCYSciSparcN/AN/A$2.65 per share1.51$1.38 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRGBullfrog AI-$5.36M-$0.86N/A∞N/AN/A-141.39%-124.63%5/9/2025 (Estimated)EDSAEdesa Biotech-$6.17M-$1.87N/AN/AN/AN/A-233.69%-124.14%5/9/2025 (Estimated)LPCNLipocine-$16.35M-$0.01N/A∞N/AN/A-19.17%-17.60%5/8/2025 (Estimated)SPRCYSciSparc-$3.48M$14.940.27N/AN/AN/AN/AN/AN/ALatest SPRCY, LPCN, BFRG, and EDSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025N/AEDSAEdesa Biotech-$0.30N/AN/AN/AN/AN/A3/14/2025Q4 2024BFRGBullfrog AIN/A-$0.18N/A-$0.18N/AN/A2/14/2025Q1 2025EDSAEdesa Biotech-$0.31-$0.48-$0.17-$0.48N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRGBullfrog AIN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/ASPRCYSciSparcN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRGBullfrog AIN/A5.905.90EDSAEdesa BiotechN/A1.090.91LPCNLipocineN/A12.9712.97SPRCYSciSparcN/A11.052.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRGBullfrog AI0.96%EDSAEdesa Biotech5.50%LPCNLipocine9.11%SPRCYSciSparcN/AInsider OwnershipCompanyInsider OwnershipBFRGBullfrog AI33.90%EDSAEdesa Biotech22.60%LPCNLipocine6.12%SPRCYSciSparcN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRGBullfrog AI49.42 million5.76 millionNot OptionableEDSAEdesa Biotech207.02 million2.60 millionNot OptionableLPCNLipocine105.35 million5.02 millionNo DataSPRCYSciSparc21.04 millionN/ANot OptionableSPRCY, LPCN, BFRG, and EDSA HeadlinesRecent News About These CompaniesSciSparc: AutoMax announces $13M first delivery of JAC vehiclesDecember 26, 2024 | markets.businessinsider.comSciSparc Announces Spin-Off Plans with Miza III VenturesDecember 17, 2024 | markets.businessinsider.comSciSparc plans to sell MitoCareX stake for enhanced valuationSeptember 28, 2024 | uk.investing.comSciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - MorningstarSeptember 19, 2024 | morningstar.comSciSparc Ltd: SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 MillionAugust 30, 2024 | finanznachrichten.deBaked tomatoes with spicy sausageMay 24, 2024 | nzherald.co.nzTeen died from eating a spicy chip as part of social media challenge, autopsy report concludesMay 18, 2024 | kcci.comA Teen Died of Too Much Chile After Eating a Spicy Chip, Autopsy SaysMay 18, 2024 | time.comLatest News for SciSparc Stock (NASDAQ:SPRC)April 11, 2024 | benzinga.comTop 10 Hot Young OnlyFans & Spicy Young OnlyFans ModelsMarch 27, 2024 | laweekly.comSpicy PalomaFebruary 27, 2024 | pbs.orgPokemon Indigo Disk Crispin guide – How to make a spicy sandwich and how to beat CrispinJanuary 3, 2024 | videogamer.comYour Body on Spicy Food: The Good and Bad Ways It Affects Your HealthSeptember 23, 2023 | everydayhealth.comTeen’s death after spicy chip challenge halts sales, unleashes concernsSeptember 12, 2023 | pennlive.comSnack company removes spicy ‘One Chip Challenge’ product after teen’s deathSeptember 10, 2023 | washingtonpost.com22 Spicy Perfumes For Fall 2023 That Smell Cozy & ComfortingSeptember 1, 2023 | bustle.comA Spicy Regenerative RecieverJune 7, 2023 | hackaday.comGrilled Oysters With Spicy Garlic Butter and Parmesan Bread CrumbsMay 20, 2023 | wsj.comClearmind Medicine Inc. (CMND)May 6, 2023 | ca.finance.yahoo.comJake Gyllenhaal Chases His Spicy Wings With a Classic WatchApril 21, 2023 | gq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPRCY, LPCN, BFRG, and EDSA Company DescriptionsBullfrog AI NASDAQ:BFRG$1.81 +0.04 (+2.26%) Closing price 04:00 PM EasternExtended Trading$1.80 -0.01 (-0.28%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Edesa Biotech NASDAQ:EDSA$2.37 -0.03 (-1.25%) Closing price 03:50 PM EasternExtended Trading$2.36 -0.02 (-0.63%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Lipocine NASDAQ:LPCN$3.26 -0.02 (-0.61%) Closing price 04:00 PM EasternExtended Trading$3.35 +0.09 (+2.79%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.SciSparc OTCMKTS:SPRCYSciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to perform a pre-clinical study for the evaluation of SCI-210 drug development program for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
